Disulfiram may be an effective pharmacotherapy for cocaine dependence because it removes alcohol use as a cue to cocaine use, prevents the use of alcohol to enhance euphoria and alleviate dysphoric effects associated with binge cocaine use, and prevents the formation of cocaethylene, an active metabolite formed during cocaine-alcohol abuse whch may contribute to both euphoria and cocaine-associated toxicity. This double-blind, placebo-controlled, within subjects study (n=7) examined the effect of disulfiram treatment on acute intranasal cocaine (placebo, 1mg/kg or 2 mg/kg) administration in human volunteers. Effects of disulfiram on cocaine pharmacokinetics, physiological and behavioral responses were determined. Disulfiram treatment increased systemic exposure to cocaine with significant increases in maximal plasma cocaine contentrations. Disulfiram significantly increased cocaine-associated cardiovasuclar responses, including heart rate and blood pressure. Disulfiram treatment blunted peak """"""""high"""""""" for cocaine 1 mg/kg dose, but increased """"""""high"""""""" for the cocaine 2 mg/kd dose. At later time points (60 minutes after cocaine administration) both disulfiram doses accentuated negative/stimulant effects of cocaine, but responses were greatest for disulfiram 250 mg/d treatment. The production of negative effects suggest an additional rationale for disulfiram as an aversive therapy for cocaine dependence. Disulfiram 500 mg/kg alone treatment significantly increased heart rate and diastolic blood pressure and was associated with nonsignificantly greater cocaine concentrations indicating a greater potential for toxicity relative to the lower disulfiram dose. Disulfiram 250 mg/kg (or lower doses) may have potential as a pharmacotherapy for cocaine dependence, particularly in concurrent alcohol abusers. Future plans include: 1) recruitment of additional female subjects and analyzing the data while stratifying by gender and 2) conducting a study with a similar design, but using lower doses of disulfiram (125 mg daily and 62.5 mg daily) to determine whether these doses will have greater efficacy and less potential for toxic interactions with cocaine.

Project Start
1997-04-01
Project End
1997-11-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
34
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Kelsey, Megan M; Braffett, Barbara H; Geffner, Mitchell E et al. (2018) Menstrual Dysfunction in Girls From the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study. J Clin Endocrinol Metab 103:2309-2318
Kleinberger, Jeffrey W; Copeland, Kenneth C; Gandica, Rachelle G et al. (2018) Monogenic diabetes in overweight and obese youth diagnosed with type 2 diabetes: the TODAY clinical trial. Genet Med 20:583-590
Berkowitz, Robert I; Marcus, Marsha D; Anderson, Barbara J et al. (2018) Adherence to a lifestyle program for youth with type 2 diabetes and its association with treatment outcome in the TODAY clinical trial. Pediatr Diabetes 19:191-198
Kriska, Andrea; El Ghormli, Laure; Copeland, Kenneth C et al. (2018) Impact of lifestyle behavior change on glycemic control in youth with type 2 diabetes. Pediatr Diabetes 19:36-44
Askie, Lisa M; Darlow, Brian A; Finer, Neil et al. (2018) Association Between Oxygen Saturation Targeting and Death or Disability in Extremely Preterm Infants in the Neonatal Oxygenation Prospective Meta-analysis Collaboration. JAMA 319:2190-2201
Venditti, E M; Tan, K; Chang, N et al. (2018) Barriers and strategies for oral medication adherence among children and adolescents with Type 2 diabetes. Diabetes Res Clin Pract 139:24-31
Gidding, Samuel S; Bacha, Fida; Bjornstad, Petter et al. (2018) Cardiac Biomarkers in Youth with Type 2 Diabetes Mellitus: Results from the TODAY Study. J Pediatr 192:86-92.e5
Arslanian, Silva; El Ghormli, Laure; Bacha, Fida et al. (2017) Adiponectin, Insulin Sensitivity, ?-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY. Diabetes Care 40:85-93
Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628
Krystal, John H (2016) Neuroethology as a translational neuroscience strategy in the era of the NIMH Research Domain Criteria. Psychophysiology 53:364-6

Showing the most recent 10 out of 343 publications